Overview

This trial is active, not recruiting.

Condition type 2 diabetes
Sponsor China Cardiometabolic Registries
Collaborator Merck Sharp & Dohme Corp.
Start date March 2011
End date May 2014
Trial size 5000 participants
Trial identifier NCT01307410, CCMR-303-3B Extension

Summary

In 2010, the sponsor conducted an observational study, entitled as "Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with Type 2 Diabetes - 3B Study " which was to evaluate the level of cardiovascular diseases (CVD) risk factor control and its regional difference in China. As a continuation, this extension of the 3B Study is designed to assess the incidence of cardiovascular events, cardio-renal events, and other microvascular complications, in 1, 2 and 3 years in patients with type 2 diabetes and with high risk of (CVD) with or without existing or history of coronary artery diseases.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients with hypertension and dyslipidemia with prior CAD
Patients with hypertension and dyslipidemia without prior CAD

Primary Outcomes

Measure
Incidence of CVD events
time frame: 3 years

Secondary Outcomes

Measure
Annual incidence of microvascular complications
time frame: 3 years

Eligibility Criteria

Male or female participants at least 40 years old.

Inclusion Criteria: - Age 40 years or older - Outpatients who meet the inclusion and exclusion criteria of 3B study - With hypertension,dyslipidemia and one of the following: - History of acute coronary artery disease or ischemic stroke - Age > 65 years old - Overweight or obesity (BMI > 24 kg/m2) - Microalbuminuria or albuminuria - Current smoker Exclusion Criteria: - Patients with type 1 DM - Pregnant or breast feeding women - Patients who are unable to or not willing to return for follow up visits every 6 months for 3 years; - Patients have severe heart failure (NYHA Class III-IV) - Patients with severe renal deficiency (creatinine clearance < 30 ml/min) - Patients who are not willing to sing the informed consent form; - Patients who are participating in any other interventional clinical studies,

Additional Information

Official title A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China - 3B Extension A Study of China Cardiometabolic Registries (CCMR)
Principal investigator Linong Ji, MD
Description Limited by its cross sectional design, 3B study was not be able to provide any information on how various patterns of treatment and prescribing behaviors would impact the outcomes of prevention of cardiovascular and cardio-renal diseases in type 2 diabetes longitudinally. This information, however, would be crucial in better guiding the real world medical practice and maximizing the effectiveness of medical treatment for better controlling cardiovascular risk factors. The 3B Extension study is thus designed to extend the 3B study by continuing to follow up on enrolled patients for 3 years. The 3B Extension study is expected to demonstrate the clinical outcomes of nationally representative type 2 diabetes patients who are treated by endocrinologists, cardiologists and nephrologists separately in all tiers of hospitals, as measured by diabetes progression, incidence of cardiovascular complications, and incidence of microvascular complications. It will be the first study of this scale in China based on its exclusivity, extensiveness, and the level of government and national thought leaders' support. It will be conducted in collaboration with the advisory board of China Cardiometabolic Registries (CCMR).
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by China Cardiometabolic Registries.